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Abstract We describe a successful living donor liver
transplantation (LDLT) using a lymphocytotoxic cross-
match highly positive graft. A 41-year-old woman with
alcoholic liver cirrhosis was referred as a potential candi-
date for LDLT, and her husband was willing to donate his
partial liver. As the T-lymphocytotoxic crossmatch titer
was over 10,0009, the patient was ﬁrst infused with rit-
uximab for preoperative desensitization, and then ﬁve
rounds of plasmapheresis were performed. After the third
plasmapheresis, the lymphocytotoxic crossmatch test was
negative. A left liver graft including the caudate lobe
was implanted, and anti-CD25 antibody (basiliximab) was
administered on postoperative days 1 and 4. The postop-
erative course was uneventful except for an episode of mild
acute cellular rejection on postoperative day 27. Although
the impact of a lymphocytotoxic crossmatch-positive liver
graft on acute cellular rejection and graft survival in LDLT
remains controversial, perioperative desensitization may
provide beneﬁts when using a highly sensitized liver graft.
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Introduction
Renal transplantation rates are low among patients highly
sensitized to human leukocyte antigen (HLA) because of
the high rate of antibody-mediated rejection and sub-
sequent graft loss. It was recently reported, however, that
preoperative desensitization using an anti-CD 20 antibody
(rituximab) and intravenous immunoglobulin improved
transplantation rates in patients highly sensitized to HLA
[1]. In contrast, the signiﬁcance of a positive lymphocy-
totoxic crossmatch in living donor liver transplantation
(LDLT) is controversial. Successful LDLT using a liver
graft in which the lymphocytotoxic crossmatch was highly
positive is reported.
Case report
The recipient was a 41-year-old woman with end-stage
liver disease due to alcoholic liver cirrhosis (model for end-
stage liver disease score 21). At the age of 20, she was
gravida one, para one. She was considered a candidate for
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encephalopathy. Because of the severe shortage of cadav-
eric donor grafts in Japan, we planned an LDLT, and her
husband was willing to donate his partial liver. The ABO
blood type was identical, but the T lymphocytotoxic
crossmatch titer was over 10,0009 and the B lymphocy-
totoxic crossmatch titer was 1289 (complement method
with the dilution technique according to the standard
National Institutes of Health technique) [2]. In addition, an
examination of anti-HLA antibodies using ﬂuorescent
microspheres revealed that the recipient had donor speciﬁc
antibodies (B51 and B52). The number of HLA mis-
matches was three. After obtaining written informed con-
sent from the patient and donor and the approval of the
intra-institutional committee, we proceeded to the preop-
erative preparations.
For preoperative desensitization, the patient was ﬁrst
infused with rituximab 2 weeks before the scheduled sur-
gery (due to a catheter-associated infection, however, the
operation was postponed and LDLT was performed
21 days after initiation of the rituximab therapy). As the
antibody to hepatitis B core antigen was positive, entecavir
(0.5 mg/day) was administered for 3 weeks preoperatively
to prevent a possible hepatitis B virus breakthrough. Five
rounds of plasmapheresis were performed. After the third
plasmapheresis, the lymphocytotoxic crossmatch test was
negative, and was sustained as negative thereafter.
A left liver graft including the caudate lobe was implan-
ted. During the LDLT, splenectomy was performed. On
postoperative days 1 and 4, 20 mg of anti-CD25 antibody
(basiliximab) was administered in addition to the routine
methylprednisolone and tacrolimus, as we were anxious
about hyperacute rejection. Besides, mycophenolate mofetil
(MMF; 2,000 mg/day) was started on postoperative day 7.
The postoperative course was uneventful except for an epi-
sode of mild acute cellular rejection (Banff score 3) on
postoperative day 27, which responded promptly to steroid
recycle therapy. The liver biopsy specimen obtained at the
time of the acute rejection showed mild inﬁltration of lym-
phocytes in the portal area and around the bile ducts. The
clinical course of the recipient is summarized in Fig. 1. One
year after the LDLT, the lymphocytotoxic crossmatch
remained negative and the patient has been well with good
graft function.
Discussion
The impact of a lymphocytotoxic crossmatch-positive liver
graft on acute cellular rejection and graft survival remains
controversial, both in deceased donor liver transplantation
[3, 4] and in LDLT [5–7]. Some institutions have reported
signiﬁcantly unfavorable outcomes in LDLT recipients
with a positive lymphocytotoxic crossmatch [6, 7]. In
contrast, our previous results [5] showed that if the titer is
low (no more than 329), a positive lymphocytotoxic
crossmatch does not adversely affect the graft or survival in
patients without desensitization. Although the signiﬁcance
of a quantitative assessment of the lymphocytotoxic
crossmatch has not been reported, the high titer in our
present patient led to the need for perioperative desensiti-
zation to prevent early graft loss due to antibody-mediated
rejection. After considering the results in the present
patient, we have settled the indication criteria for preop-
erative desensitization therapy at the titer of 1,0009
(T lymphocyte crossmatch).
Fig. 1 The clinical proﬁle of
the present patient. ACR acute
cellular rejection, ALT alanine
aminotransferase, MMF
mycophenolate mofetil, MP
methylprednisolone, PE plasma
exchange, TB total bilirubin,
POD postoperative day
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to have arisen through pregnancy. Therefore, we applied
preoperative desensitization using rituximab and plasma-
pheresis to reduce the high titer of preformed antibodies
and B lymphocytes. As a result, the lymphocytotoxic
crossmatch was negative after the 3rd plasmapheresis, and
negativity was sustained thereafter. Preoperative desensi-
tization using rituximab was introduced in ABO-incom-
patible LDLT in 2003 and has dramatically improved the
outcomes of ABO-incompatible LDLT. The appropriate
dosage of rituximab is still controversial, but many previ-
ous studies have reported the administration of 375 mg/m
2
of rituximab 1–3 weeks before the transplant. Following
these successful cases, we planned the administration of
375 mg/m
2 (500 mg/body) of rituximab 2 weeks before
the operation [8, 9]. In addition, we performed splenectomy
during the LDLT. Splenectomy is also considered to be
effective to reduce antibody production, as the spleen is the
site of antibody production. After the operation, the sup-
pression of T-cell function to prevent the initiation of
T-cell-mediated antibody production was regarded as
indispensable. We have routinely used tacrolimus and
steroid as an immunosuppressive regimen, and in this
particular patient, we added basiliximab (postoperative
days [PODs] 1 and 4) and MMF. Mild acute cellular
rejection occurred about 3 weeks after the LDLT, but
response to the steroid recycle therapy was prompt, and the
lymphocytotoxic crossmatch was negative during this
episode.
In summary, we report a successful LDLT using a
lymphocytotoxic crossmatch highly positive graft. Periop-
erative desensitization using plasmapheresis and rituximab
may provide signiﬁcant beneﬁts for reducing anti-HLA
antibodies.
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